PT - JOURNAL ARTICLE AU - Geller, Frank AU - Wu, Xiaoping AU - Lammi, Vilma AU - Abner, Erik AU - Valliere, Jesse Tyler AU - Nastou, Katerina AU - Rasmussen, Morten AU - Andersson, Niklas Worm AU - Quinn, Liam AU - DBDS Genomic Consortium AU - Aagaard, Bitten AU - Banasik, Karina AU - Bliddal, Sofie AU - Boding, Lasse AU - Brunak, Søren AU - Brøns, Nanna AU - Bybjerg-Grauholm, Jonas AU - Christoffersen, Lea Arregui Nordahl AU - Didriksen, Maria AU - Dinh, Khoa Manh AU - Erikstrup, Christian AU - Feldt-Rasmussen, Ulla AU - Grønbæk, Kirsten AU - Kaspersen, Kathrine Agergård AU - Mikkelsen, Christina AU - Nielsen, Claus Henrik AU - Nielsen, Henriette Svarre AU - Nielsen, Susanne Dam AU - Nissen, Janna AU - Sequeros, Celia Burgos AU - Tommerup, Niels AU - Ullum, Henrik AU - Estonian Biobank Research Team AU - FinnGen AU - Spiliopoulos, Lampros AU - Bager, Peter AU - Hviid, Anders AU - Sørensen, Erik AU - Pedersen, Ole Birger AU - Lane, Jacqueline M AU - Lassaunière, Ria AU - Ollila, Hanna M AU - Ostrowski, Sisse Rye AU - Feenstra, Bjarke TI - Central role of glycosylation processes in human genetic susceptibility to SARS-CoV-2 infections with Omicron variants AID - 10.1101/2024.11.21.24317689 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.21.24317689 4099 - http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317689.short 4100 - http://medrxiv.org/content/early/2024/11/22/2024.11.21.24317689.full AB - The host genetics of SARS-CoV-2 has previously been studied based on cases from the earlier waves of the pandemic in 2020 and 2021, identifying 51 genomic loci associated with infection and/or severity. SARS-CoV-2 has shown rapid sequence evolution increasing transmissibility, particularly for Omicron variants, which raises the question whether this affected the host genetic factors. We performed a genome-wide association study of SARS-CoV-2 infection with Omicron variants including more than 150,000 cases from four cohorts. We identified 13 genome-wide significant loci, of which only five were previously described as associated with SARS-CoV-2 infection. The strongest signal was a single nucleotide polymorphism (SNP) intronic of ST6GAL1, a gene affecting immune development and function, and connected to three other associated loci (harboring MUC1, MUC5AC and MUC16) through O-glycan biosynthesis. We also found further evidence for an involvement of blood group systems in SARS-CoV-2 infection, as we observed association 1) for a different lead SNP in the ABO locus indicating a protective effect of blood group B against Omicron infection, 2) for the FUT2 SNP tagging secretor status also reported for SARS-CoV-2 infection with earlier variants, and 3) for the strongest expression quantitative trait locus (eQTL) for FUT3 (Lewis gene). Our study provides robust evidence for individual genetic variation related to glycosylation translating into susceptibility to SARS-CoV-2 infections with Omicron variants.Competing Interest StatementS.Brunak has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S, Eli Lilly and Co and managing board memberships in Proscion A/S and Intomics A/S. C.E. has received unrestricted research grants from Novo Nordisk administered by Aarhus University and Abbott Diagnostics administered by Aarhus University Hospital. C.E. received no personal fees. K.G. received a Janssen Pharma research grant and is on the advisory board of Otsuka Pharma. L.B. currently works for MSD Denmark. All other authors report no competing interests.Funding StatementWe thank all participants and staff related to the Copenhagen Hospital Biobank, Danish Blood Donor Study, EFTER-COVID, FinnGen, Estonian Biobank and Mass General Brigham Biobank for their contribution to this research. This work was supported by research grants from Sygeforsikringen danmark (2020-0178) and the EU Horizon REACT study (101057129). The Copenhagen Hospital Biobank (CHB) was funded by grants from Novo Nordisk Foundation (NNF23OC0082015) and Rigshospitalet Research Council (Framework grant) and by Novo Nordisk Foundation CHALLENGE grant (NNF17OC0027594). The Danish Blood Donor Study (DBDS) was funded by the Danish Council for Independent Research - Medical Sciences and the Danish Administrative Regions (Bio- and Genome Bank Denmark). S. Bliddal received grants from the Novo Nordisk Foundation (NNF22OC0077221,NNF23OC0087269), L.A.N.C. was funded by NordForsk (project number 105668 and 138929), B.F. was partially supported by the Novo Nordisk Foundation (NNF17OC0027594). The Danish Departments of Clinical Microbiology (KMA) and Statens Serum Institut carried out laboratory analyses, registration, and release of the national SARS-CoV-2 surveillance data for the present study. The work of the Estonian Genome Center, University of Tartu, was funded by the European Union through Horizon 2020 research and innovation program under grants no. 894987, 101137201 and 101137154, and Estonian Research Council Grant PRG1291. The Estonian Genome Center analyses were partially carried out in the High Performance Computing Center, University of Tartu. We want to acknowledge the participants and investigators of the FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure (https://www.bbmri-eric.eu/national-nodes/finland/). Finnish Biobank Cooperative -FINBB (http://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious services (https://site.fingenious.fi/en/) managed by FINBB. We thank the Mass General Brigham Biobank for providing samples, genomic data, and health information data for genetic analyses. We acknowledge support from NIH R01AI170850 (J.V.), NIH R35GM146839 (J.M.L.) and NIH R01HG012810 (J.M.L.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Copenhagen Hospital Biobank provides biological left-over samples from routine blood analyses and the patients were not asked for informed consent before inclusion. Instead, patients were informed about the opt-out possibility to have their biological specimens excluded from use in research. Individuals from the exclusion register (Vaevsanvendelsesregistret) were excluded from the study. For the Danish Blood Donor Study, informed consent was obtained from all participants. Both studies are part of a COVID-19 protocol approved by the National Ethics Committee (H-21030945) and the Danish Data Protection Agency (P-2020-356). EFTER-COVID was conducted as a surveillance study as part of Statens Serum Instituts advisory tasks for the Danish Ministry of Health. According to Danish law, these national surveillance activities do not require approval from an ethics committee. Participation in the study was voluntary and the invitation letter contained information about participants rights under the Danish General Data Protection Regulation (rights to access data, rectification, deletion, restriction of processing and objection). After reading this information, it was considered informed consent when participants read the information and agreed, and then continued to fill in the questionnaires. The activities of the Estonian Biobank (EstBB) are regulated by the Human Genes Research Act, which was adopted in 2000 specifically for the operations of EstBB. Individual level analysis with EstBB data was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs), using data according to release application 6-7/GI/5933 from the Estonian Biobank. Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. The FinnGen study is approved by the Finnish Institute for Health and Welfare and other authorities (a complete overview of permissions is given in the Supplementary Note). The Mass General Brigham (MGB) Biobank, formerly known as the Partners Biobank, is a hospital-based cohort study produced by the MGB healthcare network located in Boston, MA. The MGB Biobank contains data from patients in multiple primary care facilities, as well as tertiary care centers located in the greater Boston area. Participants of the study are recruited from inpatient stays, emergency department environments, outpatient visits, and through a secure online portal available to patients. Recruitment and consent are fully translatable to Spanish in order to promote a greater patient diversity. This allows for a systematic enrollment of diverse patient groups which is reflective of the population receiving care through the MGB network. For the MGB Biobank, all patients provide written consent upon enrollment. Furthermore, the MGB cohort included test verified SARS-CoV-2 infection data with time of diagnosis. The present study protocol was approved by the MGB Institutional Review Board (#2018P002276). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGWAS meta-analysis summary statistics are available for interactive plotting and viewing via LocusZoom56 (https://my.locuszoom.org/gwas/962995/?token=0fa64e3ae9d445ddb7b5bd3a32c6b4d6) and will be made public and deposited at https://www.danishnationalbiobank.com/gwas/ after publication. Complete FUMA results (including the MAGMA analysis) are available online (https://fuma.ctglab.nl/browse/475677). https://my.locuszoom.org/gwas/962995/?token=0fa64e3ae9d445ddb7b5bd3a32c6b4d6 https://fuma.ctglab.nl/browse/475677